A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of
efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque
psoriasis who previously participated in Study ACD2600g.